An adolescent with familial hypercholesterolemia was started on a statin medication. He now presents with severe, progressive muscle weakness and markedly elevated creatine kinase levels. An investigation reveals the presence of anti-HMG-CoA reductase antibodies. What is the most appropriate next step in management?